Clinical Trials Browser

Phase 2 × spartalizumab × Tumor-Agnostic × Clear all

NCT03693326 2018-10-03

PDR001 in Patients With Non-small Cell Lung Cancer Harboring KRAS/NRAS Mutation or no Actionable Genetic Abnormalities

Phase 2 Unknown

Neoplasms